N4 Pharma says that recent formulation work for Nuvec has demonstrated inconsistencies with previous studies and the share price has nearly halved in the past fortnight.
Nuvec is a potential nanoparticle drug delivery technology. The in vitro tests produced positive results but this was not replicated in in vivo tests. Further experiments will be undertaken in order to define protocols and methodology to ensure that the tests are standardised.
News about further studies should be available by the end of the summer.
There should be enough cash to last until the end of 2019, thanks to a recent £1m placing at 10p a share. The current share price is 4.15p.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
CEPS is selling its investment in the CEM group.
Food ingredients supplier Real Good Food is showing some signs of improvement but there is a long way to go.
Better news from telecoms hardware supplier Filtronic, which is trading in line with expectations.